Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pfizer's Xeljanz: The Slow Road To Blockbuster Status

pills

Related Content

Pfizer’s Tofacitinib Clears FDA Without Limited Indication

Nov 06 2012

Xeljanz Development Plans Scaled Back By Pfizer

Oct 27 2015

Pfizer Eyes Xeljanz Expansion To Ulcerative Colitis

Sep 21 2015

Pfizer Will Support Inflectra Launch With Dedicated Sales Force

Nov 14 2016

Baricitinib Complete Response May Put Lilly/Incyte Behind IL-6 Blockers In RA

Apr 14 2017

Pfizer's Xeljanz Set To Lag Lilly's Olumiant In Europe Following Past Rebuffs

Jan 27 2017

Pfizer Assembling New Commercial Team For Move Into Dermatology

Oct 19 2016

Related Companies

Pfizer Inc.

AbbVie Inc.

Amgen, Inc.

Eli Lilly and Company

Incyte Corporation

GSK plc

Johnson & Johnson

Sanofi

Regeneron Pharmaceuticals, Inc.

Additional Topics

Clinical Trials Business Strategies Launches Commercial Inflammation BioPharmaceutical

More from Immunological

More from Therapeutic Category

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window